Addendum No. 1 to Supply Contract Between JSC Isotope and IsoRay Medical Inc.
JSC Isotope and IsoRay Medical Inc. have agreed to extend their existing contract for the supply of Cs-131 until December 31, 2017. The addendum also provides for the delivery of additional lots of Cs-131, with specific quantities and contract amounts omitted for confidentiality. All other terms of the original contract remain unchanged. This addendum is considered an integral part of the original agreement and may be executed via email.
Exhibit 10.1
ADDENDUM No. 1
to Contract No. 840/08625142/25/158-15
dtd. December 07, 2015
| Moscow | December 09, 2016 |
JSC “Isotope”, Pogodinskaja, 22, Moscow, 119435 Russia hereinafter named to as “the Sellers’’, and The Company IsoRay Medical Inc., 350 Hills Street, Suite 106, Richland, WA ###-###-#### USA, hereinafter named to as “the Buyers” concluded the present Addendum about the following:
| 1. | To prolong the terms of validity of the present contract till the 31st of December 2017. |
| 2. | To deliver additionally under present contract [**] lots of Cs-131 with activity of [**] Ci each. |
| 3. | The sum of the contract [**]. |
| 4. | The present addendum is the integral part of contract 840/08625142/25/158-15 and may be signed by E-mail. |
| 5. | All the rest terms of Contract No. 840/08625142/25/158-15 remain unchanged. |
| THE SELLERS | THE BUYERS | ||
| /s/ B.V. Aakaiev | /s/ Thomas C. LaVoy | ||
| B.V. Aakaiev | Thomas C. LaVoy | ||
| Director General, JSC “Isotope” | CEO – IsoRay Medical Inc. | ||
| 22.12.16 | December 14, 2016 |
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
